Home > Analytics > SUN PHARMA ADVANCED RESEARCH COMPANY

SUN PHARMA ADVANCED RESEARCH COMPANY
Intrinsic Value | Fundamental Analysis

BOM : 532872     NSE : SPARC    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward
Pledged Shares : None or < 25%
Jun 11,2025
Price(EOD): ₹ 165.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Business Support
MCap: ₹ 5,381.83 Cr
Value of ₹ 1 Lac invested in SUN PHARMA ADVANCED RESEARCH COMPANY
on Jun 11,2020 (price: ₹ 148.30)

₹ 1 L

₹ 1.12 L

1W : 2.3% 1M : 10.6% 1Y : -25%
COMMUNITY POLL
for SUN PHARMA ADVANCED RESEARCH COMPANY
Please provide your vote to see the results
SUN PHARMA ADVANCED RESEARCH COMPANY is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Industry Peers & Returns1W1M1Y
SUN PHARMA ADVANCED RESEARCH COMPANY 2.3% 10.6% -25%
SYNGENE INTERNATIONAL 2.4% 5.4% -3.9%
SAGILITY INDIA 2.8% -10.8% NA
LATENT VIEW ANALYTICS 1.3% -1.8% -16.1%
JUST DIAL 2.5% -1.9% -4.1%
AWFIS SPACE SOLUTIONS -2.4% 7.4% 69.5%
MEDI ASSIST HEALTHCARE SERVICES 1.9% 6.6% -1.3%
JAYKAY ENTERPRISES NA -2.6% 142.2%
ECOS (INDIA) MOBILITY & HOSPITALITY 10% 52.6% NA

FUNDAMENTAL ANALYSIS OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Fundamentals Score
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Valuation Score
[As on : Jun 11,2025 ]

Ratio Consolidated
P/E
P/B
P/S
-15.71
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -342.51 Cr
[Latest Qtr - Mar2025 - Consolidated Results ]

-24.81
P/B Calculated based on Book Value of Rs -216.95 Cr
[Latest Year - Mar2025 - Consolidated Results ]

74.99
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 71.77 Cr
[Latest Qtr - Mar2025 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 16% undervalued companies ! Discover More →

FAIR VALUE OF SUN PHARMA ADVANCED RESEARCH COMPANY

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
NA
109%
119%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SUN PHARMA ADVANCED RESEARCH COMPANY



SUN PHARMA ADVANCED RESEARCH COMPANY vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SUN PHARMA ADVANCED RESEARCH COMPANY

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.38
0
-0.37
-
0.37
0
-
0.12
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SUN PHARMA ADVANCED RESEARCH COMPANY

Pledged Promoter Shares
0 %
As on : Mar2025

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SUN PHARMA ADVANCED RESEARCH COMPANY

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
82.36%
27.83%
23.63%
24.83%
64.19%
49.75%
42.44%
43.5%
QtrlyTrend
8
Latest Qtr: Mar2025
Quarterly Result Analysis →


SUN PHARMA ADVANCED RESEARCH COMPANY related INDICES

BSE Indices1W1M1Y
BSE ALLCAP 6.4% 8.9% 7.5%
BSE MIDSMALLCAP 4.7% 9% 8.4%
BSE HEALTHCARE 3.1% 5.8% 23.7%
BSE 250 SMALLCAP INDEX 2.8% 11% 13.4%
BSE SMALLCAP 2.7% 11.5% 17.3%
NSE Indices1W1M1Y
NIFTY MICROCAP 250 3.1% 11.9% 20.6%
NIFTY TOTAL MARKET 2.4% 4% 11.2%

You may also like the below Video Courses


FAQ about SUN PHARMA ADVANCED RESEARCH COMPANY


Is SUN PHARMA ADVANCED RESEARCH COMPANY good for long term investment?

As on Jun 11,2025, the Fundamentals of SUN PHARMA ADVANCED RESEARCH COMPANY look Poor and hence it may not be good for long term investment ! See Financial Performance of SUN PHARMA ADVANCED RESEARCH COMPANY . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SUN PHARMA ADVANCED RESEARCH COMPANY UnderValued or OverValued?

As on Jun 11,2025, SUN PHARMA ADVANCED RESEARCH COMPANY is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY ?

As on Jun 11,2025, the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY is Rs. 77.46 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. -931.70
Fair Value [Median EV / Sales Model] : Rs. 79.28
Fair Value [Median Price / Sales Model] : Rs. 75.64
Estimated Median Fair Value of SUN PHARMA ADVANCED RESEARCH COMPANY : Rs. 77.46

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SUN PHARMA ADVANCED RESEARCH COMPANY trading at a Premium or Discount?

As on Jun 11,2025, SUN PHARMA ADVANCED RESEARCH COMPANY is trading at a Premium of 114% based on the estimates of Median Intrinsic Value!